Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report
Ticker: PRNAF · Form: 6-K · Filed: Jul 31, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, cash-flow, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K with its latest cash flow report, relevant for its S-8 and F-3 filings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on July 31, 2024, to incorporate by reference its Quarterly Activities/Appendix 4C Cash Flow Report. This filing is being included in various registration statements on Form S-8 and Form F-3, indicating ongoing securities offerings or updates.
Why It Matters
This filing provides an update on Alterity's financial activities and cash flow, which is crucial for investors to assess the company's operational status and funding.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the underlying financial health and operational progress of a development-stage biotech company like Alterity Therapeutics carry inherent risks.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- 0001013762-24-002902 (filing_id) — Accession Number
- 20240731 (date) — Filing Date
- Form S-8 (filing_type) — Incorporated by reference into
- Form F-3 (filing_type) — Incorporated by reference into
- 333-251073 (registration_statement_id) — Form S-8 File Number
- 333-274816 (registration_statement_id) — Form F-3 File Number
- Prana Biotechnology Ltd (company) — Former Company Name
FAQ
What is the purpose of incorporating this 6-K into existing registration statements?
The 6-K is incorporated by reference into Alterity's Registration Statements on Form S-8 and Form F-3 to provide updated information relevant to those filings, likely related to ongoing securities offerings or employee stock plans.
What specific report is being submitted as part of this 6-K?
Exhibit 99.1, the Quarterly Activities/Appendix 4C Cash Flow Report, is submitted as part of this Form 6-K.
When was Alterity Therapeutics Limited previously known as?
Alterity Therapeutics Limited was formerly known as Prana Biotechnology Ltd, with a name change date of January 5, 2001.
Where is Alterity Therapeutics Limited's principal executive office located?
The principal executive office of Alterity Therapeutics Limited is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates it files annual reports under cover of Form 20-F.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-07-31 06:23:35
Filing Documents
- ea0210334-6k_alterity.htm (6-K) — 13KB
- ea021033401ex99-1_alterity.htm (EX-99.1) — 145KB
- ex99-1_001.jpg (GRAPHIC) — 322KB
- ex99-1_002.jpg (GRAPHIC) — 13KB
- ex99-1_003.jpg (GRAPHIC) — 2KB
- 0001013762-24-002902.txt ( ) — 624KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Quarterly Activities/Appendix 4C Cash Flow Report 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: July 31, 2024 2